S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Something is Coming for America's Top Stock (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Something is Coming for America's Top Stock (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Something is Coming for America's Top Stock (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Something is Coming for America's Top Stock (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
OTCMKTS:DNPUF

Sumitomo Pharma (DNPUF) Stock Forecast, Price & News

$3.64
0.00 (0.00%)
(As of 10/3/2023 ET)
Compare
Today's Range
$3.64
▼
$3.64
50-Day Range
$3.59
▼
$4.37
52-Week Range
$3.59
▼
$7.60
Volume
N/A
Average Volume
1,467 shs
Market Capitalization
N/A
P/E Ratio
0.06
Dividend Yield
395.36%
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest

Sumitomo Pharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.50mentions of Sumitomo Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.83 out of 5 stars

See Top Rated MarketRank™ Stocks Here

DNPUF stock logo

About Sumitomo Pharma (OTCMKTS:DNPUF) Stock

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

DNPUF Price History

DNPUF Stock News Headlines

October 2, 2023 | msn.com
Signal: Sumitomo invests in Nano One Materials Corp
September 12, 2023 | technews.tmcnet.com
Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program
October 4, 2023 | Legacy Research (Ad)
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
July 30, 2023 | markets.businessinsider.com
Here's what Wall Street expects from Sumitomo Dainippon Pharma's earnings
July 18, 2023 | technews.tmcnet.com
Ginkgo Bioworks and Sumitomo Chemical Announce Expanded Partnership To Develop Functional Chemicals with Synthetic Biology
June 24, 2023 | forbes.com
Sumitomo Metal Industries
June 1, 2023 | msn.com
Sumitomo Dainippon Pharma (TYO:4506) Price Target Decreased by 10.51% to 868.46
May 26, 2023 | markets.businessinsider.com
3 Pharma Stocks That Will Boom Thanks to AI
October 4, 2023 | Legacy Research (Ad)
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
May 2, 2023 | msn.com
Sunovion, Sumitomo To Lay Off 223 At Marlborough Offices
April 3, 2023 | benzinga.com
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America
April 3, 2023 | markets.businessinsider.com
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America
February 3, 2023 | reuters.com
Nippon Paper, others look at making sustainable aviation fuel from wood
November 3, 2022 | forbes.com
Japan’s Sumitomo Mitsui Boosts Stake In Philippines’ RCBC With $460 Million Investment
October 20, 2022 | finance.yahoo.com
Sumitomo Pharma Co., Ltd. (DNPUF)
October 4, 2022 | markets.businessinsider.com
Revisiting Myovant...
October 3, 2022 | bloomberg.com
Sumitomo Offers to Buy All of Myovant in Deal Worth $2.5 Billion
September 10, 2022 | reuters.com
Sumitomo Pharma Co Ltd
July 30, 2022 | reuters.com
Japan's Sumitomo Mitsui reports Q1 profit jump, Mizuho suffers drop
July 28, 2022 | markets.businessinsider.com
Here's what Wall Street expects from Sumitomo Dainippon Pharma's earnings report
May 4, 2022 | finance.yahoo.com
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
February 22, 2022 | yahoo.com
Sumitomo Dainippon Pharma Oncology Appoints Jatin J. Shah, M.D. as Chief Medical Officer
November 3, 2021 | prnewswire.com
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma
October 28, 2021 | markets.businessinsider.com
Sumitomo Dainippon Pharma is about to announce its earnings — here's what Wall Street expects
October 21, 2021 | prnewswire.com
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma
August 5, 2021 | nasdaq.com
Sumitomo Dainippon Pharma Co. Ltd (DNPUF)
July 27, 2021 | markets.businessinsider.com
Here's what to expect from Sumitomo Dainippon Pharma's earnings report
See More Headlines
Receive DNPUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sumitomo Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:DNPUF
CUSIP
N/A
CIK
N/A
Web
www.ds-pharma.com
Phone
81 6 6203 5321
Fax
N/A
Employees
6,250
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
0.06
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Hiroshi Nomura (Age 66)
    CEO, Pres & Representative Director
    Comp: $688.52k
  • Mr. Toru Kimura Ph.D. (Age 63)
    Sr. Mngg Exec. Off. of Glo. Crprate Stgy, F&A, Regen & Cell Med. Off., Kobe Ctr, Mfg. Plt and Dir.
  • Mr. Hiroyuki Baba (Age 64)
    Mngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off. & Director
  • Mr. Naoki Noguchi
    Exec. Officer of Corp. Governance & Communications, VP and Head of Corp. Communications
  • Mr. Takuya Taguchi
    M.E.O. of Sales & Marketing Div., SVP, Hd of Sales & Marketing Div. and Dep. Hd of Japan Bus. Unit
  • Ms. Atsuko Higuchi
    Managing Exec. Officer of External Affairs, Corp. Secretariat & HR
  • Mr. Yoshiharu Ikeda Ph.D. (Age 65)
    Managing Exec. Officer of Drug Research Division, Head of Japan Bus. Unit & Director
  • Mr. Koichi Kozuki
    E.O. of R. Aff., Med. Sci., C.R.C. & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus.
  • Dr. Shigeyuki Nishinaka Ph.D. (Age 59)
    Managing Exec. Officer of Bus. Devel. & Management and Director
  • Mr. Isao Shimizu
    Exec. Officer, Sr. VP, Head of Drug Research Division & Sr. Exec. Research Director

Key Competitors

View All Competitors













DNPUF Stock - Frequently Asked Questions

Should I buy or sell Sumitomo Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sumitomo Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DNPUF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNPUF, but not buy additional shares or sell existing shares.
View DNPUF analyst ratings or view top-rated stocks.

How have DNPUF shares performed in 2023?

Sumitomo Pharma's stock was trading at $7.40 at the start of the year. Since then, DNPUF stock has decreased by 50.9% and is now trading at $3.6350.
View the best growth stocks for 2023 here.

Are investors shorting Sumitomo Pharma?

Sumitomo Pharma saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 5,538,000 shares, an increase of 14.4% from the August 31st total of 4,842,500 shares. Based on an average daily volume of 5,200 shares, the short-interest ratio is presently 1,065.0 days.
View Sumitomo Pharma's Short Interest.

Is Sumitomo Pharma a good dividend stock?

Sumitomo Pharma (OTCMKTS:DNPUF) pays an annual dividend of $14.37 per share and currently has a dividend yield of 1.27%. The dividend payout ratio is 24.70%. This payout ratio is at a healthy, sustainable level, below 75%.

What is Sumitomo Pharma's stock symbol?

Sumitomo Pharma trades on the OTCMKTS under the ticker symbol "DNPUF."

How do I buy shares of Sumitomo Pharma?

Shares of DNPUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sumitomo Pharma's stock price today?

One share of DNPUF stock can currently be purchased for approximately $3.64.

How many employees does Sumitomo Pharma have?

The company employs 6,250 workers across the globe.

How can I contact Sumitomo Pharma?

Sumitomo Pharma's mailing address is 2-6-8 Dosho-machi, Osaka, 541-0045. The official website for the company is www.ds-pharma.com. The company can be reached via phone at 81 6 6203 5321.

This page (OTCMKTS:DNPUF) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -